Glycosaminoglycans (GAG), one of the major constituents of connective tissues, are long, unbranched polysaccharides that can contain as many as 100 sugar residues per chain (Muir and Hardingham, 1975) . They are normally present not as free chains but grouped together in large numbers with each chain covalently linked at one end (the reducing terminus) to a central protein core, the whole forming a single proteoglycan molecule. Each GAG chain is composed of alternating residues of uronic acid and hexosamine, except for an atypical trisaccharide linkage region at the reducing terminus. In keratan sulphate, however, uronic acid is replaced by galactose. The hexosamine residues (D-glucosamine or D-galactosamine) are usually-N-acetylated and 0-sulphated, but N-sulphate groups are often present in heparin and heparan sulphate. The uronic acid residues are either D-glucuronic or L-iduronic, with the latter often being sulphated.
Catabolism of GAG is a complicated process. Complete chains can be degraded into smaller fragments by the action of endoglycosidases acting on susceptible internal linkages such as, for example, testicular hyaluronidase (EC 3.2.1.35), which can degrade chondroitin sulphates and hyaluronic acid to produce tetra-and hexasaccharides and has a similar but more limited action on dermatan sulphate. Similarly, an endoglycosidase found in human platelets (Wasteson et al., 1970) can degrade heparan sulphate to produce a range of GAG fragments, the smallest equivalent in size to a hexasaccharide. Complete catabolism to release constituent monosaccharides and inorganic sulphate then requires the concerted action of a number of different lysosomal exoglycosidase and sulphatase enzymes that remove one sugar residue or sulphate group at a time from the non-reducing terminal end of the remaining partially degraded GAG chains. A deficiency in any one of these enzymes interrupts the sequence, leading to intracellular accumulation of partially degraded GAG as lysosomal storage products and their excretion in large amounts in urine. To date seven such enzyme deficiencies have been described (Table 1) . They give rise to the group of irnerited diseases of connective tissue known as the mucopolysaccharidoses.
Cultured fibroblasts and corrective factors
The discovery of the nature of the defect in each type of mucopolysaccharidosis arose mainly from the work of Neufeld and her collaborators (Fratantoni et al., 1968 (Fratantoni et al., , 1969 , who showed that when skin fibroblasts from different types of mucopolysaccharidosis were grown together in culture they were able to correct abnormal accumulation of GAG (measured as precipitable 35S04) in each others' cells. They further demonstrated that this correction could be achieved simply by adding medium in which cells of a different genotype had been cultured previously, due to the release of soluble 'corrective factors'. These 'corrective factors' were subsequently identified as lysosomal enzymes Bach et al., 1973; Kresse, 1973; O'Brien, 1972; Hall et al., 1973; Matalon et al., 1974; Fluharty et al., 1974; GniotSzulzycka and Donnelly, 1976; Singh et al., 1976) . Because normal fibroblasts produce all these lysosomal enzymes they are able to correct every type of mucopolysaccharidosis. They are released into the extracellular environment from whence they are taken up by active endocytosis into pinocytotic vesicles (von Figura and Kresse, 1974; Brot et al., 1974; Hickman et al., 1974) which can then fuse with lysosomes containing partially degraded GAG. Lysosomal deficiency diseases like the mucopolysaccharidoses are thus ideally suited to replacement therapy with an external source of active enzymes.
Replacement therapy by plasma infusion
The discovery that the mucopolysaccharidoses were a related group of lysosomal enzyme deficiency diseases prompted a number ofattempts atreplacement therapy, with normal plasma as the most readily available source of active enzymes. The first attempt was made by Di Ferrante et al. (1971) , who infused about 1 1 of plasma into one child with Hurler's disease and two with Hunter's disease. This was followed by a transfusion of leucocytes suspended in a small volume of autologous plasma into another patient with Hunter's disease (Knudson et al., 1971) . These transfusions induced increased breakdown and excretion of dermatan and heparan sulphates, while 120 Dean et al. (1973) and one with Hunter's disease (Dean et al., 1975a) . The changes seen in these cases after infusion included an increased excretion of uronic acid (see Fig. 1 ) and an increase in the relative proportions of lower molecular weight oligosaccharides separated by chromatography on Sephadex G-25 (Fig. 2) . These changes were consistent with those expected from increased breakdown and mobilisation of excreted GAG and were not seen when one of the patients with Sanfilippo's disease was infused with an equivalent volume of iso-osmotic dextran solution one year later (Dean et al., 1975b) , indicating that the increased output of degraded GAG was a specific phenomenon, attributable to lysosomal enzymes in plasma. Yatziv et al. (1975) also noted transient increases in urinary oligosaccharides derived from heparan sulphate after giving fresh plasma to two siblings with Hunter's disease. Accompanying clinical changes included a decrease in the size of liver and spleen, improved joint mobility, accelerated growth, and a decrease in the incidence of respiratory infections.
In contrast, Dekaban et al. (1972) found that infusions of plasma or whole blood had little effect on patients with Hurler's, Hunter's, and Sanfilippo's diseases, while Moser et al. (1974) found that infusions of HLA-compatible leucocytes in Sanfilippo type B disease produced only a transient increase in GAG catabolism. Undoubtedly the differing degrees of response to this form of enzyme replacement therapy were due in part to differences in activity of the enzyme administered, while the transitory nature of the improvements observed is not surprising in view of the short intracellular half lives of many lysosomal glycosidases and sulphatases (Porter et al., 1971; Hickman and Neufeld, 1972; O'Brien et al., 1973; Figura and Kresse, 1974) . Frequent infusions are therefore required to maintain high levels of enzyme activity and long-term replacement therapy by this method is impracticable.
Fibroblasts in replacement therapy
The in-vitro studies of Neufeld's group established that normal skin fibroblasts release lysosomal enzymes. which can then be taken up by deficient fibroblasts and restore their capacity to degrade GAG (Fratantoni et al., 1968 (Fratantoni et al., , 1969 Hickman et al., 1974) . When circulating enzyme concentrations are raised by infusions of plasma transient increases in catabolism and excretion of stored GAG ensue Dean et al., 1973 Dean et al., , 1975a  L.M. (Dean et al., 1973) . Yatziv et al., 1975) . Amalgamation of these two sets of data suggests that skin fibroblasts themselves might provide a more continuous source of lysosomal enzymes in vivo and thus increase the rate of catabolism of accumulated GAG over an extended period of time. This possibility was examined by Dean et al. (1975c) , who supplied fibroblasts as a skin allograft in a boy with Hunter's disease and noted a significant increase in excretion of uronic acid, particularly oligosaccharides of lower molecular weight, after grafting. When these oligosaccharides were fractionated by chromatography on Sephadex G-25 the relative proportions of oligosaccharides of lowest molecular weight increased (Fig. 3) , while at the same time the sulphate/hexuronic acid molar ratio of the highest molecular weight fraction fell from an abnormally high value of almost 2:1 in preimplantation samples to a normal level of 1:1 in samples taken after treatment. This increased catabolism and desulphation of accumulated oligosaccharides suggested that the circulating level of a-L-idurono-2-sulphate sulphatase (deficient in Hunter's disease) had increased after the grafting. This assumption was confirmed by the increased excretion of 'corrective factor' (which contains a-Lidurono-2-sulphate sulphatase) in the patient's urine. It rosefrom a level below 1 U/24h to nearly 4 U/24h, and enzyme output and catabolism of accumulated O'Brien et al., 1973) suggests that a relatively small number of cells can have a disproportionately large effect.
The effectiveness of fibroblast transplantation was assessed by analysis of urinary GAG and oligosaccharides to determine the effect of donor cells on the rate of catabolism of accumulated dermatan and heparan sulphates. In addition, the appearance of Hunter corrective factor in urine was measured by the method of Cantz et al. (1972) and a-L-idurono-2-sulphate sulphatase activity measured directly in serum and leucocytes using an [3H]-labelled disulphated disaccharide as a substrate (Lim et al., 1974) . During this measurement of enzyme activity radioactive monosulphated reaction products were separated from the remaining disulphated substrate by ion-exchange chromatography on columns of ECTEOLA cellulose (Liebaers and Neufeld, 1976) .
CHANGES IN EXCRETED GAG AFTER TRANSPLANTATION
There was an immediate increase in total uronic acid excreted by each patient after transplantation, mainly in the form of oligosaccharides of low molecular weight, as would be expected from an increased rate of catabolism of accumulated GAG. Fig. 4 shows data for one of the patients who received fibroblasts (case 1). In addition to the increased excretion of oligosaccharides there was also a small increase in output of GAG. The reason for this is not yet clear.
The Bio-Gel P-2 elution profiles of uronic acidcontaining oligosaccharides separated from patients' urine before transplantation were compared with those obtained from normal children. Although four fractions were resolved from both normal and pathological samples the relative proportions were different, with pathological urines containing considerably more of the larger oligosaccharides (Components I and II, Fig. 5 Dean et al. (1978) by permission of the publishers). group.bmj.com on May 29, 2017 -Published by http://jcp.bmj.com/ Downloaded from the elution profiles changed to resemble closely those of normal urine (Fig. 5) . These changes were again consistent with those expected from increased catabolism of oligosaccharides.
Since the pronounced deficiency of a-L-idurono-2-sulphate sulphatase in Hunter's disease leads to a break in catabolism of dermatan and heparan sulphates, leaving a sulphated iduronic acid residue at the non-reducing terminus of accumulated GAG and oligosaccharides, the sulphate :uronic acid molar ratios of the oligosaccharide component I separated by chromatography on Bio-Gel P-2 were determined. Values were abnormally high in all three patients before transplantation, ranging from 1-6:1 to 2-0:1, compared with the normal value of 1-0:1 (see Table 2 ). After transplantation the sulphate:hexuronic acid ratios decreased to a level at or a little below that of age-matched control samples and remained low throughout the period monitored. In addition to the decrease in sulphate content of fraction I the iduronic acid content of the monosaccharide fraction (fraction IV) estimated by glc was found to be considerably higher in pooled samples analysed after transplantation than in those sampled before treatment (see Table 3 ). Both of these observations strongly suggest an increase in a-L-idurono-2-sulphate sulphatase activity subsequent to transplantation, with the removal of sulphate groups from non-reducing terminal iduronic acid groups allowing them in turn to be removed by a-L-iduronidase, which is not normally deficient in Hunter's disease.
CHANGES IN ACTIVITY OF IDURONATE SULPHATASE
Protein concentrates prepared from patients' urine by precipitation with ammonium sulphate (Dean et al., 1975c) were tested for the presence of Hunter 'corrective factor' (which contains a-L-idurono-2-sulphate sulphatase) by their ability to correct abnormal 35S-sulphate incorporation by the patients' own fibroblasts (Cantz et al., 1972) . Samples of urine collected before transplantation were almost totally devoid of activity, with mean values < 0 5 U/24 h (Fig. 6) . In contrast, samples collected after transplantation were much more active, with mean values ranging from about 3 U/24 h to more than 11 U/24 h for each patient ( Table 2 Sulphate/uronic acid molar ratios oJ oligosaccharide component I separated on Bio-Gel P-2. Group A samples were collected 0-3 months before transplantation, group B samples from I week to 6 months after transplantation, and group C samples from 6 months to 2 years after transplantation. Each group was rechromatographed on Bio-Gel P-2. Sodium ions, which interfere with S04 determination, were removed on a column of Dowex-50 (H+ form) before analysis. Number of samples pooled in each group given in parentheses (from Dean et al., 1978 , by permission of the publishers)
2-14 (3) 0-54 (7) 0-87 (2) 3 1-60 (6) 095 (7) 093 (4) Control 1-02 -- Table 3 Effect of fibroblast transplantation on proportion of iduronic acid in monosaccharide fraction elutedfrom Bio-Gel P-2. Iduronic acid content of monosaccharide expressed as percentage of total uronic acid. Group A samples were collected 0-6 weeks before transplantation, group B samples 0-3 months after transplantation, and group C samples 6-16 months after transplantation. Number of samples pooled in each group given in parentheses. Relative amounts oJ glucuronic and iduronic acids in each group were determined by glc after conversion to trimethylsilyl derivatives, and iduronic acid expressed as a percentage of the total hexuronic acid and the leucocyte homogenate had 10 times the activity of an untreated control.
Discussion
Transplantation of histocompatible normal fibroblasts increased the activity of a-L-idurono-2-sulphate sulphatase when measured in the urine of all three transplanted patients as corrective factor. This increase in activity was unaffected either by decreasing dosage or total withdrawal of the immunosuppressive drugs given to decrease the risk of rejection. The raised enzyme levels found by direct measurement in the serum and leucocytes of the treated patients were present in blood samples collected at least one year after the end of immunosuppressive therapy and between 15 and 3 years after transplantation. Dean et al., 1978 by permission of the publishers).
these GAG, and particularly of the oligosaccharides derived from them, increased after treatment. The abnormal molecular size distribution of oligosaccharides separated by chromatography on Bio-Gel P-2 before treatment changed to a more normal size distribution, the sulphate:uronic acid ratio of oversulphated fractions fell to normal values, and the iduronic acid content of the monosaccharide fraction Table 4 Mean 24-hour excretion of Hunter corrective factor before and after transplantation. Values represent mean units of correction (as defined by Barton and Neufeld, 1971 ) ± SE from all samples analysed. Numbers ofanalyses in parentheses (from Dean et al., 1978, by (3) rose after transplantation. All these changes persisted after the end of immunosuppressive therapy and were again consistent with those expected from increased catabolism of accumulated oligosaccharides.
Both host and donor cells were fully HLA compatible and gave no mixed leucocyte reaction. Because of this the transplanted cells were probably not rejected and continued to produce lysosomal enzymes, including a-L-idurono-2-sulphate sulphatase, which could then be endocytosed into the lysosomes of host cells. The ability of the respective donor fibroblasts to correct abnormal 35SO4 metabolism in each of the patient's cells in vitro (Dean et al., 1976 (Dean et al., , 1978 had been shown before transplantation. Probably this ability may persist after transplantation, since active endocytosis of the appropriate lysosomal enzymes in vitro has been shown by fibroblasts cultured from patients with Sanfilippo's disease and /3-glucuronidase deficiency (O'Brien et al., 1973; Figura and Kresse, 1974; Kaplan et al., 1977) . Transfer of lysosomal enzymes from normal donor cells to deficient recipient cells is also known to take place in vivo. For example, lymphocytes from a natural chimeric male calf deficient in a-mannosidase took up a-mannosidase from the blood cells of its normal female co-twin r at an early stage of fetal development (Jolly et al., 1976) . Similarly, /3-glucuronidase can be transferred from normal to deficient cells in mosaic tissues of tetraparental mice (Feder, 1976) , while heterozygous females with Hunter's disease have two populations of cells, one of which is as deficient in a-L-idurono-2-sulphate sulphatase as cells from affected patients (Migeon et al., 1977 (Kihara et al., 1973) or a-mannosidosis (Mersmann et al., 1976) -transplantation of normal fibroblasts may be ofvalue in treating a wide range of other deficiency diseases.
